## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1615

AITKEN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP04/003518

FILED: 2 APRIL 2004

U.S. APPLICATION NO: 10/550,381

35 USC §371 DATE: 21 SEPTEMBER 2005

FOR: COMBINATIONS COMPRISING ANTI-EPILEPTIC DRUGS FOR

THE TREATMENT OF NEUROLOGICAL DISORDERS

MS: Amendment
Commissioner for Patents

PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 21, 2005. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. These references are of record in the instant PCT application PCT/EP04/003518, copies are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Daniel J. Woods

Attorney for Applicants

Reg. No. 59,864

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080 (862) 778-9587

Date: 2/17/09